Compare Stocks → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATOSNASDAQ:CRDFNASDAQ:JYNTNASDAQ:VERU Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Therapeutics$1.63+1.9%$1.62$0.62▼$2.31$204.99M1.271.38 million shs953,316 shsCRDFCardiff Oncology$3.54$4.68$0.94▼$6.42$158.31M2.021.35 million shs550,706 shsJYNTJoint$16.35-1.8%$13.49$7.31▼$17.82$244.76M1.5889,501 shs84,404 shsVERUVeru$1.39-2.1%$1.11$0.36▼$1.92$203.47M-0.472.33 million shs1.13 million shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Therapeutics+1.91%+9.59%+16.79%+56.86%+120.08%CRDFCardiff Oncology-2.48%+1.72%-18.62%+108.24%+108.24%JYNTJoint-3.31%+1.22%+36.70%+61.81%+12.73%VERUVeru+7.58%+6.77%+8.40%+181.69%+24.56%Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATOSAtossa Therapeutics2.0275 of 5 stars3.53.00.00.02.71.70.0CRDFCardiff Oncology1.1292 of 5 stars3.52.00.00.02.60.00.0JYNTJoint3.1142 of 5 stars3.31.00.00.03.33.31.9VERUVeru1.762 of 5 stars3.41.00.00.02.53.30.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Therapeutics3.00Buy$5.50237.42% UpsideCRDFCardiff Oncology3.00Buy$10.50196.61% UpsideJYNTJoint2.50Moderate Buy$22.0034.56% UpsideVERUVeru2.80Moderate Buy$4.00187.77% UpsideCurrent Analyst RatingsLatest JYNT, CRDF, VERU, and ATOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2024ATOSAtossa TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight5/14/2024VERUVeruB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$5.005/13/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $6.005/13/2024VERUVeruHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.005/6/2024CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.005/6/2024JYNTJointB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $20.005/6/2024VERUVeruHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$2.00 ➝ $3.005/3/2024JYNTJointRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $16.004/16/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.004/15/2024VERUVeruOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$7.00 ➝ $5.004/2/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00(Data available from 5/21/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa TherapeuticsN/AN/AN/AN/A$0.73 per shareN/ACRDFCardiff Oncology$490K323.08N/AN/A$1.56 per share2.27JYNTJoint$117.70M2.08$0.69 per share23.73$1.68 per share9.73VERUVeru$16.30M12.48N/AN/A$0.22 per share6.32Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Therapeutics-$30.09M-$0.24N/AN/AN/AN/A-32.79%-31.25%8/12/2024 (Estimated)CRDFCardiff Oncology-$41.44M-$0.90N/AN/AN/A-6,594.92%-54.54%-47.11%8/14/2024 (Estimated)JYNTJoint-$9.75M-$0.75N/A25.95N/A-9.24%3.94%1.29%9/11/2024 (Estimated)VERUVeru-$93.15M-$0.34N/AN/AN/A-265.27%-130.13%-67.82%8/8/2024 (Estimated)Latest JYNT, CRDF, VERU, and ATOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2024N/AATOSAtossa Therapeutics-$0.07-$0.05+$0.02-$0.05N/AN/A4/1/2024Q4 2023ATOSAtossa TherapeuticsN/A-$0.06-$0.06-$0.06N/AN/A4/1/2024Q1 2024VERUVeruN/A-$0.09-$0.09-$0.10N/A$2.14 million3/7/2024Q4 2023JYNTJoint$0.03$0.07+$0.04$0.89$29.63 million$30.61 million2/29/2024Q4 2023CRDFCardiff Oncology-$0.26-$0.21+$0.05-$0.21$0.08 million$0.16 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa TherapeuticsN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/AJYNTJointN/AN/AN/AN/AN/AVERUVeruN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa TherapeuticsN/A16.3416.34CRDFCardiff OncologyN/A5.915.91JYNTJointN/A1.341.34VERUVeruN/A4.724.22OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Therapeutics12.74%CRDFCardiff Oncology16.29%JYNTJoint76.88%VERUVeru47.16%Insider OwnershipCompanyInsider OwnershipATOSAtossa Therapeutics7.80%CRDFCardiff Oncology6.30%JYNTJoint30.20%VERUVeru14.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Therapeutics12125.76 million115.95 millionOptionableCRDFCardiff Oncology3144.72 million41.91 millionOptionableJYNTJoint44414.97 million10.45 millionOptionableVERUVeru189146.38 million125.60 millionOptionableJYNT, CRDF, VERU, and ATOS HeadlinesRecent News About These CompaniesMay 20 at 8:54 PM | marketbeat.comWorth Venture Partners LLC Invests $616,000 in Veru Inc. (NASDAQ:VERU)May 20 at 10:22 AM | lutontoday.co.ukA&E Navigators at Luton and Bedford hospitals help young people facing violenceMay 20 at 6:42 AM | americanbankingnews.comVeru Inc. (NASDAQ:VERU) CEO Mitchell Shuster Steiner Sells 28,066 SharesMay 19 at 7:00 AM | americanbankingnews.comMitchell Shuster Steiner Sells 84,021 Shares of Veru Inc. (NASDAQ:VERU) StockMay 18 at 10:41 AM | insidertrades.comMitchell Shuster Steiner Sells 28,066 Shares of Veru Inc. (NASDAQ:VERU) StockMay 17, 2024 | investing.comVeru Inc. CEO sells over $246k in company stockMay 17, 2024 | investing.comVeru Inc. executive buys $9,999 in company stockMay 17, 2024 | americanbankingnews.comVeru Inc. (NASDAQ:VERU) Expected to Post Q3 2024 Earnings of ($0.05) Per ShareMay 16, 2024 | marketbeat.comEquities Analysts Issue Forecasts for Veru Inc.'s Q3 2024 Earnings (NASDAQ:VERU)May 15, 2024 | globenewswire.comVeru Announces Steven B. Heymsfield M.D.May 15, 2024 | americanbankingnews.comVeru (NASDAQ:VERU) Coverage Initiated at B. RileyMay 15, 2024 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Veru (NASDAQ:VERU)May 14, 2024 | globenewswire.comVeru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology WeekMay 14, 2024 | marketbeat.comB. Riley Initiates Coverage on Veru (NASDAQ:VERU)May 14, 2024 | markets.businessinsider.comBuy Rating for Veru Inc. on Promising Enobosarm Trials and Strategic Market PositioningMay 13, 2024 | bovnews.comIt’s Better to Hope for Prosperity than Become Adversary: Veru Inc (VERU) StockMay 13, 2024 | marketbeat.comVeru's (VERU) Buy Rating Reiterated at HC WainwrightMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed on Veru Amid Strong Clinical Prospects and Solid Financial PositionMay 9, 2024 | finance.yahoo.comVeru Inc (VERU) Q2 2024 Earnings Call Transcript Highlights: Strategic Focus and Financial RecoveryMay 8, 2024 | msn.comVERU Stock Earnings: Veru Misses EPS, Beats Revenue for Q2 2024May 8, 2024 | finanznachrichten.deVeru Inc.: Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical ProgramNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAtossa TherapeuticsNASDAQ:ATOSAtossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Cardiff OncologyNASDAQ:CRDFCardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.JointNASDAQ:JYNTThe Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.VeruNASDAQ:VERUVeru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.